20/20 Biolabs, Inc.
No financial data available for AIDX.
Company may not file with SEC or CIK is unresolved.
20/20 BioLabs reported Q1 2026 revenue of $0.4 million, down from $0.6 million in Q1 2025, with state-funded firefighter cancer screening programs expected to drive meaningful revenue growth in Q2 2026
“The first quarter of 2026 was a transformational period for 20/20, marked by our direct listing on the Nasdaq Capital Market”
No Form 4 transactions on record.
Informational purposes only, not investment advice.